We evaluated whether reduced-dose chemotherapy with 2 days of idarubicin (12 mg/m 2 ) and 5 days of cytarabine (100 mg/m 2 ) (2 þ 5) is effective for patients aged 65 -74 by retrospectively comparing the results with those aged 55 -64 treated with 3 þ 7. In 1999 -2009, we treated 20 patients aged 65 -74 with 2 þ 5, and 23 patients aged 55 -64 with 3 þ 7. The complete remission rates by the first induction were 50.0 and 69.6% for older and younger groups (P ¼ 0.203). Two-year overall survival rates were 55.9 and 32.3% for older and younger groups; 2-year rates of relapse-free survival for all these patients were 15.7 and 36.5%. The differences in overall and relapse-free survival were statistically insignificant (P ¼ 0.726 and 0.413, respectively). The treatment results of 2 þ 5 for the older group were not significantly worse compared with those of 3 þ 7 for the younger. Therefore, elderly patients who do not tolerate 3 þ 7 should still benefit from 2 þ 5.
INTRODUCTION
Several studies report that the rates of complete remission (CR) for the elderly patients with acute myeloid leukemia (AML) are 60%, but the remission periods are short with the median survival being 5 -10 months, and the probability of remaining in remission for 3 years after diagnosis is ,10% (1 -3) . Recent studies show that intensifying the anthracycline doses for the induction therapy for AML improves the rates of CR and overall survival (OS) (4, 5) . There exist conflicting reports, however, showing that intensifying the doses of chemotherapy may be too toxic to elderly patients, and therefore, reduced chemotherapy doses may be of benefit in these patients. It still remains to be proven whether the decreased dose of the induction therapy for elderly patients with AML is appropriate or not, in terms of overall and relapse-free survival (RFS).
Compared with daunorubicin (DNR), idarubicin (IDR) at the dose of '3 þ 7' is as effective as increased DNR (6) , and therefore, even if reduced doses of IDR are used in remission induction, the induction regimen may cause a comparably good response in induction chemotherapy without increasing the life-threatening side effects, including profound neutropenia. In this regard, we employed a reduced dose of IDR in the induction therapy for elderly patients with AML, who are aged !65. Here, we retrospectively evaluated the outcomes of the reduced-dose induction therapy for elderly patients with AML by comparing the overall and relapse-free rates of survivals with those of the slightly younger patients who were treated with the standard dose of induction therapy.
PATIENTS AND METHODS
Patients aged 55 -74, who presented at the University of Tokyo Hospital and were newly diagnosed as AML from January 1999 to December 2009, were retrospectively analyzed. Patients diagnosed as acute promyelocytic leukemia (APL) were excluded. We stratified those patients into two groups: the younger group, aged 55 -64 at diagnosis, who were treated with the standard induction therapy consisting of three daily doses of IDR (12 mg/m 2 ) and 7 days of continuous infusion of cytarabine (Ara-C, 100 mg/m 2 ) (3 þ 7); and the older group, aged 65 -74 at diagnosis, who were treated with the reduced induction therapy consisting of two daily doses of IDR (12 mg/m 2 ) and 5 days of continuous injection of Ara-C (100 mg/m 2 ) (2 þ 5), respectively. The age of the patient (!65 years old) was the only criterion for applying the reduced regimen.
A statistical comparison was performed using two-sided t-tests. The karyotypes of the chromosomes were categorized into three groups as defined by an MRC AML10 trial (7) . The observation period for each patient is from the day on which the patient was diagnosed as AML. The patients who were transferred to other hospitals and were lost from follow-up were excluded at the time of transfer. We also reviewed the number of chemotherapies required to achieve hematologic CR for each patient.
Adverse events of the patients were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0, in which the laboratory findings of disseminated intravascular coagulation (DIC) were evaluated according to the Japanese Ministry of Health, Labor and Welfare criteria (8) .
We estimated the 2-year overall and RFS by the KaplanMeier method, using GNU R version 2.10.1. Furthermore, we searched the risk factors that may affect the overall and RFS by analyzing the patients' data with the univariate Cox proportional hazards model, using JMP w 8.0. Retrospective analyses of patients have been approved by the institutional ethics committee and have been performed in accordance with the institutional and national guidelines.
RESULTS
Of the patients aged 55 -74, 43 non-treated patients were newly diagnosed with AML (non-APL) from January 1999 to December 2009, and received induction chemotherapy. Twenty of them were at age 65 -74 (older group; median age 68) and 23 of them were at age 55 -64 (younger group; median age 59), and underwent the decreased-dose therapy (IDR þ Ara-C, 2 þ 5) and the standard-dose therapy (IDR þ Ara-C, 3 þ 7), respectively. Table 1 provides the demographic and clinical characteristics of the patients at their diagnoses. Among patients treated with IDR þ Ara-C, younger patients exhibited poorer performance statuses, and older patients had more adverse karyotype risks.
The consolidation therapy for 13 patients (81.3%) in the younger group after achieving the first CR was high-dose Ara-C (2000 mg/m 2 Â 2, Days 1 -5 for age 55 -59, and 1500 mg/m 2 Â 2, Days 1 -5 for age 60 -64), and the consolidation therapy for 4 patients (40.0%) in the older group after achieving the first CR was IDR þ Ara-C (2 þ 5), the same as the induction therapy. The first consolidation therapy for the other patients varied, such as IDR þ Ara-C ( Days 1 -5) (three in the younger group and one in the older group), due to the delayed recovery of the blood counts and severe non-hematologic toxicities. When CR was not achieved by the initial induction therapy, the same regimens were repeated for the reinduction therapy.
We evaluated both the chance of achieving CR in the first induction therapy and the chance of death without achieving CR using index variables (Table 1) . Sixteen patients (69.6%) in the younger group achieved hematologic CR by the first induction therapy of IDR þ Ara-C (3 þ 7), and 10 patients (50.0%) in the older group achieved hematologic CR by the first induction therapy of IDR þ Ara-C (2 þ 5) (P ¼ 0.203). Five patients (21.7%) of the younger group and three patients (15.0%) of the older group died without achieving CR (P ¼ 0.578).
Only one patient in the older group died of treatment-related mortality after the initial induction therapy, to whom G-CSF was administered for severe neutropenia and sepsis but died of septic shock and multiple-organ failure. The most common adverse events (Grade 2 or more) observed in older and younger groups after the initial induction therapy were febrile neutropenia [100 and 95.7% (P ¼ 0. Six patients in the older group and four patients in the younger group either underwent the second regimens or died without reaching the absolute neutrophil count (ANC) over 1000/ml. For other patients, the median durations for recovery of the ANC over 1000/ml were 33 days (range: 21 -70) and 32 days (range: 23-46) for older and younger groups, respectively. Likewise, four in the older group and two in the younger group either underwent the second regimens or died without reaching the platelet count over 100 000/ml, and the median durations for recovery of the platelet count over 100 000/ml were 26.5 days (range: 20 -51) and 27 days (range: 21-40) for older and younger groups, respectively.
We evaluated the OS and the RFS by the Kaplan -Meier method, and compared the results between these two groups (Fig. 1) . The 2-year rates of OS were 32.3% for patients treated with 3 þ 7 (younger group), and were 55.9% for patients treated with 2 þ 5 (older group). The difference in rates of OS between these two groups was statistically insignificant (P ¼ 0.726). The 2-year rates of RFS were 36.5% for patients treated with 3 þ 7 (younger group), and were 15.7% for patients treated with 2 þ 5 (older group). The difference in RFS between these two groups was also statistically insignificant (P ¼ 0.413).
We used the univariate proportional hazards model to figure out which characteristics of the patients serve as the risk factors to affect the rates of survival (Table 2 ). For OS, none of these characteristics were statistically significant with the data for all, younger and older patients, although the karyotype risks for all patients tend to affect the OS (P ¼ 0.0949). For RFS, the karyotype risks for all and younger patients were statistically different and, therefore, we may consider karyotype risks as the risk factors to affect the rates of RFS. The Decreased-dose IDR for the elderly with AML 
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RFS of older and younger patients did not differ across the post-remission therapies (P ¼ 0.590 for the older group, between IDR þ Ara-C (2 þ 5) and other regimens; P ¼ 0.084 for the younger group, between high-dose Ara-C and other regimens).
DISCUSSION
Although intensive anthracycline in elderly patients with AML causes improved survival, toxicity of the treatment is comparably high (4, 5) . The reported 20% of treatmentrelated mortality (TRM), when increased doses of DNR are employed for the remission induction therapy, might be considered too high (5) . In contrast to the reports in favor of intensified chemotherapy for older patients with AML, Kantarjian et al. retrospectively analyzed the clinical courses of 446 older patients with AML, aged !70 years, and concluded that although intensified chemotherapy results in an improved CR rate, toxicities of the chemotherapy were excessively high, and the courses remain poor (9) . The randomized study for elderly patients with AML by Pautas et al. showed that anthracycline dose intensification is of no clinically relevant benefit (10).
Although Dobashi et al. present favorable outcomes of administering DNR for elderly patients with AML by expanding the total period of infusion instead of increasing the daily dose of DNR (11), IDR gives higher rates of OS and RFS than DNR in most of other studies (12 -15) , while some other studies present statistically indifferent outcomes (16) .
In our present study, the decreased dose of IDR þ Ara-C (2 þ 5) resulted in statistically insignificant difference in the rates of OS and RFS for patients at age !65 when compared with the standard 3 þ 7 for patients slightly younger. Furthermore, both the rates of deaths without achieving CR and the chance of achieving CR in the first induction therapy were not statistically different between the two age groups. This observation is of interest, because age is a major risk factor for the AML treatment. This may be because older 1050 Decreased-dose IDR for the elderly with AML patients with a poor general status were not given intensive induction therapy including 2 þ 5, while slightly younger patients were given 3 þ 7 in spite of the poorer condition. Supporting this, older patients who were treated with 2 þ 5 showed a better performance status than the slightly younger patients, as shown in Table 1 . Therefore, a further prospective study is required to determine whether reduced chemotherapy may benefit the younger patients and improve survival. Although intensified chemotherapy for elderly patients often results in too much toxicity, it remains unclear whether reduced chemotherapy for AML in turn benefits those patients. Our results here provide evidence for this issue, suggesting that reduced chemotherapy with IDR þ Ara-C should be a reasonable option for the treatment of patients in this age group. The tendency that DIC is observed more frequently in the older group than in the younger group even with the reduced regimen, as well as the fact that the median durations for recovery of ANC and platelet count were almost identical between the two groups, may also support our proposition that the reduced regimen is suitable for older patients.
In the previously reported articles that emphasize the benefit of dose intensification of anthracycline for elderly patients, DNR is used (5). However, a recently reported meta-analysis revealed that IDR is superior to DNR in improving survival (17) and, furthermore, TRM is observed in 20% of patients when treated with increased anthracycline (5). Therefore, the decreased dose of IDR may improve survival of the elderly patients without increasing their adverse events, and it is worth comparing the effect of the decreased dose of IDR with the increased/standard dose of DNR in the survival analysis.
